Ponad 7000 publikacji medycznych!
Statystyki za 2021 rok:
odsłony: 8 805 378
Artykuły w Czytelni Medycznej o SARS-CoV-2/Covid-19

Poniżej zamieściliśmy fragment artykułu. Informacja nt. dostępu do pełnej treści artykułu tutaj
© Borgis - Postępy Nauk Medycznych 2/2018, s. 81-88 | DOI: 10.25121/PNM.2018.31.2.81
*Hady Razak Hady1, Pawel Wojciak1, Patrycja Pawluszewicz1, Inna Diemieszczyk1, Mikolaj Czerniawski1, Regina Sierzantowicz2, Lech Trochimowicz1, Safauldeen Salim Neamah3, Viktar Strapko4, Adam Kretowski5, Jacek Dadan1, Jerzy Robert Ladny1, 6
Laparoscopic sleeve gastrectomy (LSG) as a operative method of morbid obesity treatment and resolution of its comorbidities
Laparoskopowa rękawowa resekcja żołądka jako metoda operacyjnego leczenia otyłości patologicznej i chorób współistniejących
1Ist Department of General and Endocrine Surgery, University Clinical Hospital of Bialystok, Poland
2Department of Health Sciences, Medical University of Bialystok, Poland
3Department of General Surgery, College of Medicine, University of Kufa, Iraq
4Department of General Surgery, Grodno State Medical University, Belarus
5Department of Endocrinology, Diabetology and Internal Medicine, University Clinical Hospital in Bialystok, Poland
6Department of Emergency and Disaster Medicine, Medical University of Bialystok, Poland
Wstęp. Globalna epidemia otyłości, jej szybko rosnące występowanie i zagrażające życiu powikłania są jednym z głównych wyzwań opieki zdrowotnej w XXI wieku. Badania nad współistniejącymi z otyłością zaburzeniami metabolizmu doprowadziły do opisania zespołu metabolicznego. Pilna potrzeba poszukiwania skutecznych metod leczenia otyłości patologicznej spowodowała rozwój wielu technik w chirurgii bariatrycznej, a wśród nich – stosunkowo nowej procedury nazywanej LSG, która okazała się bezpieczną i skuteczną metodą w leczeniu otyłości wraz z towarzyszącymi jej zaburzeniami metabolizmu i chorobami współistniejącymi.
Cel pracy. Celem niniejszej pracy była analiza przebiegu chorób towarzyszących otyłości oraz zmian BMI, ciśnienia krwi, poziomu glukozy, lipidów i innych parametrów metabolicznych u chorych otyłych poddanych operacji LSG i pooperacyjnej obserwacji jednorocznej.
Materiał i metody. Opracowanie bazowało na retrospektywnej analizie danych zebranych na materiale własnym podczas prospektywnego, jednorocznego badania 142 pacjentów otyłych, zoperowanych metodą LSG w naszej Klinice w latach 2012-2015. Uzyskano zgodę Komisji Bioetycznej Uniwersytetu Medycznego w Białymstoku oraz pisemne zgody pacjentów biorących udział w badaniu.
Wyniki. Analiza statystyczna danych zebranych w czasie jednorocznej obserwacji wykazała efektywną utratę masy ciała, poprawę parametrów metabolicznych glukozy i lipidów, a także częściowe lub nawet całkowite ustąpienie chorób współistniejących, w szczególności tych będących częścią zespołu metabolicznego, u większości pacjentów z otyłością patologiczną poddanych operacji LSG.
Wnioski. Laparoskopowa rękawowa resekcja żołądka (LSG) jest procedurą bezpieczną, skuteczną i leczącą także choroby współistniejące z otyłością, rekomendowaną jako pierwotne leczenie chirurgiczne pacjentów z otyłością patologiczną.
Introduction. Global pandemic of obesity, its quickly growing prevalence and life threatening comorbidities are one of the main healthcare issues of the 21st century. Research on metabolic disorders coexisting with obesity led to description of metabolic syndrome (MS). Urgent need to find effective methods of morbid obesity treatment provoked development of many bariatric surgery procedures, and among them, a relatively new procedure called LSG, that stands out to be safe and effective method in treating obesity and its comorbidities with their metabolic disorders.
Aim. Aim of the study was to analyze course of comorbidities and changes in BMI, blood pressure, glucose, lipids and other metabolism parameters in obese patients who undergone LSG procedure in 1-year follow-up.
Material and methods. The study is based on retrospective statistical analysis of own material acquired at 1-year prospective follow-up of 142 obese patients after LSG procedure, hospitalized and treated in our Clinic in years 2012 to 2015. The consent of the Bioethical Committee of Medical University of Bialystok, as well as written consent from all the subjected patients were obtained.
Results. Statistical analysis of data recorded at 1-year follow-up showed effective body weight loos, edification in glucose and lipid metabolism parameters and also total or partial remission on comorbidities, especially those forming metabolic syndrome, in majority of patients with morbid obesity subjected to LSG operation.
Conclusions. Laparoscopic sleeve gastrectomy (LSG) is safe, effective and comorbidity resolving procedure recommended as a primary surgical treatment method for patients with morbid obesity.
Global pandemic of obesity is one of the main healthcare issues of the 21st century. It has a significant impression in socioeconomic and psychosocial areas of public health’s interests. According to the newest WHO report from year 2011, number of people with BMI exceeding 30 has increased above 500 million, that makes up to 10% of worldwide population. Especially worth emphasizing is fact, that in last 30 years obesity occurrence increased almost twice among World’s population (1). Quickly increasing number of obesity cases promotes development of many important comorbidities, such as: hypertension, non-insulin dependent diabetes (NIDDM), cardiovascular diseases, sleep apneas, osteoarticular system’s diseases, depression and other (2, 3). In the last decades, much research work, aimed on reduction of mortality caused by cardiovascular diseases, that are main cause of death in general, has been taken to find associations between many metabolic disorders. In effect, the metabolic syndrome (MS) was described, named also as syndrome X, insulin resistance syndrome or deadly quartet, compromising abdominal obesity, hypertension, glucose intolerance and dyslipidemia. Conception of metabolic syndrome exists since about 80 years (4). However, only in the last decade a few trials to define it’s uniform diagnostic criteria have been taken. The most well-known definition of the metabolic syndrome belonged to World Health Organization (WHO), stated in year 1998 (5), but nowadays it has become obsolete and has only historical importance. Actually, the most commonly used definition comes from American Heart Association (AHA) (6). According to variety of metabolic syndrome’s diagnostic criteria, that result in many interpretational difficulties, there was a joint consensus published in year 2009. It states that necessary for MS diagnosis is coexistence of 3 among 5 previous criteria, without preferring obesity as a main criterion (7). In Poland, according to AHA-NHLBI definition, 23% men and 20% of women meet metabolic syndrome’s diagnostic criteria (8-12). The results of epidemiological research prove, that the metabolic syndrome is also widespread in USA (13) and Europe (5, 12). Hitherto epidemiological researches asses, that among developed countries’ population about 20-25% people meet the metabolic syndrome’s diagnostic criteria (13, 14). Proved fact is also that patients with diagnosed MS undergo myocardial infarction or stroke 3 times more often and 5 times more often develop NIDDM than general population. According to proven relationship between metabolic syndrome and increased morbidity and mortality caused by cardiovascular diseases, in connection with obesity pandemic among World’s population, reducing or stopping of wide spreading metabolic disorders is one of the most important challenges for contemporary medicine (15-17). Thus it seems obvious, that besides urgent need for effective prophylaxis of obesity, also appropriate treatment of already existing obesity cases is necessary. Interesting fact is that to certain moment, obesity was treated as a result, not as a cause of metabolic disorders. Nowadays, with contribution to bariatric surgery’s development, comes possibility to observe how much normalization of patient’s weight influences and even cures disorders in glucose and lipids metabolism. Thus it is reasonable to research among all bariatric procedures those, which not only permanently reduce body mass, but also normalize lipid levels the most and bring the best therapeutic effects in diabetes treatment (18). Among all surgical methods of morbid obesity treatment used in last 5 years, a relatively new procedure called laparoscopic sleeve gastrectomy (LSG) stands out very promising results in long- and short-term postoperative observation. These results are continuously published in actual scientific literature (19-21). LSG was first described by Iless and Marceau in 1988, as a part of duodenal switch (DS) with biliopancreatic diversion (BPD) operation (22). Further development led Johnston and affiliates to describe this method in 1993 as an isolated operation (23), and in year 1999, Gagner performed the first primary LSG. Laparoscopic sleeve gastrectomy operation technique compromises sub-total resection of stomach with creating a long, tubular gastric conduit based on minor curvature of the stomach. Weight loss and alignment in metabolic parameters within metabolic syndrome is caused not only by gastric resection itself, but also by following neurohormonal changes. LSG, as a procedure with relatively low postoperative complications risk, was at first indicated especially for super-obese patients (BMI > 60 kg/m2), with high perioperative complication risk or as a procedure following laparoscopic Roux-en-Y gastric bypass (LGBP) operation. At present, it is also recommended as a isolated, definitive and effective bariatric operation (24), providing high therapeutic effectiveness in treatment of many metabolic syndrome’s elements (20, 25).
According to fact, that LSG is one of the newest bariatric operations for morbid obesity treatment, there is few reports in scientific literature referring to its influence on obesity comorbidities. Our study aims to enrich knowledge base in this area.
The aim of this study was to analyze the influence of laparoscopic sleeve gastrectomy (LSG) procedure on diseases accompanying obesity – their partial remission, total resolution or worsening and also to collect, measure and statistically asses changes in biometric and biochemical metabolic parameters in patients with morbid obesity, who undergone this operation during 1-year follow-up.
Material and methods
Our study bases on retrospective review of prospectively collected data derived form group of 142 patients with morbid obesity, qualified to bariatric surgery and operated using LSG procedure in the 1st Department of General and Endocrine Surgery of the University Hospital in Bialystok between years 2012 to 2015 (tab. 1). The consent of the Bioethical Committee of Medical University of Bialystok, as well as written consent from all the subjected patients were obtained. All operated patients were subsequently examined in 1-year follow-up. The patient follow up visits were scheduled at 1, 3, 6 and 12 months following the surgery at which the BMI and %EWL, %EBL (percentage of excess weight loos and excess BMI loos) was calculated and the resolution of comorbid illnesses was noted. %EWL and %EBL calculations was based on guidelines from year 2007, while resolution of comorbidities was based on cessation of medicine taken, symptoms’ severity reduction and normalization of laboratory values. The patients have had diagnosed comorbidities, namely: depression, hypertension, non-insulin dependent diabetes (NIDDM), sleep apnea, chronic obstructive pulmonary disease (COPD), coronary disease, cholecystolithiasis, varicose veins of inferior limbs, hemorrhoids, deep vein thrombosis of inferior limbs, leg ulcerations, gastric and duodenal ulcers, gastritis, duodenitis, gastroesophageal reflux disease (GERD), oesophagitis, osteoarthritis of hip and knee joints, spinal pain, undergone myocardial infarction, that coexisted with obesity. Incidence percentages and numbers of these comorbidities in study group are presented in table 2.
Tab. 1. Demographic data and mean preoperative biometric values of patients in study group with deviations
N = 142Females = 78Males = 64
Age (years)45.82 ± 9.246.44 ± 12.2
Body weight (kg)144.2 ± 21.14151.3 ± 22.43
BMI (kg/m2)48.18 ± 6.551.08 ± 8.2
Tab. 2. Preoperative comorbidity types. Numbers and percentages among analyzed group of patients
Before surgical treatment
F 78M 64
Type 2 diabetes2819.71%2316.20%
Sleep apnea1510.56%2114.78%
Chronic obstructive pulmonary disease (COPD)96.33%1711.97%
Coronary disease96.33%2215.49%
Varicose veins of inferior limbs1611.26%139.15%
Deep vein thrombosis of inferior limbs32.11%21.4%
Trophic leg ulcerations64.22%85.63%
Peptic ulcer disease of stomach and duodenum117.74%149.85%
Gastritis and duodenitis2618.30%3222.32%
Gastro-esophageal reflux disease (GERD)85.63%64.22%
Hip joint osteoarthritis85.63%42.81%
Knee joint osteoarthritis42.81%53.52%
Spinal pain1913.38%2618.30%
Undergone hearth infarct0053.52%
During follow-up, also laboratory values of certain metabolism-related parameters, such as insulin, glucose, total cholesterol with LDL and HDL factions, triglycerides, urea, uric acid serum levels, were measured, recorded and monitored for their variability over the observation time. Mean preoperative values and deviations of these lab tests are collected in table 3. Our study took into account also values and deviations of HOMA-IR (homeostatic model assessment insulin resistance index), calculated from the following formula:
HOMA-IR = {[fasting insulin [uU/ml] x fasting glucose [mmol/l]}/22.5.
Tab. 3. Mean preoperative values and deviations of laboratory tested metabolic parameters
Fasting insulin (uU/L)42.4 ± 21.62
Fasting glucose (mg/dl)146.2 ± 52.30
Total cholesterol (mg/dl)221.95 ± 19.40
Triglycerides (mg/dl)176.4 ± 45.70
LDL-cholesterol (mg/dl)152.40 ± 31.30
HDL-cholesterol (mg/dl)44.20 ± 12.10
Uric acid (mg/dl)5.81 ± 1.81
Urea (mg/dl)35.34 ± 7.40
HOMA-IR12.90 ± 10.60
Statistical analysis was done using the software Statistics 6.0 for Windows. The continuous variables were expressed as mean and standard deviation and compared using Students T-test. The p value < 0.05 was considered as statistically significant.

Powyżej zamieściliśmy fragment artykułu, do którego możesz uzyskać pełny dostęp.
Mam kod dostępu
  • Aby uzyskać płatny dostęp do pełnej treści powyższego artykułu albo wszystkich artykułów (w zależności od wybranej opcji), należy wprowadzić kod.
  • Wprowadzając kod, akceptują Państwo treść Regulaminu oraz potwierdzają zapoznanie się z nim.
  • Aby kupić kod proszę skorzystać z jednej z poniższych opcji.

Opcja #1


  • dostęp do tego artykułu
  • dostęp na 7 dni

uzyskany kod musi być wprowadzony na stronie artykułu, do którego został wykupiony

Opcja #2


  • dostęp do tego i pozostałych ponad 7000 artykułów
  • dostęp na 30 dni
  • najpopularniejsza opcja

Opcja #3


  • dostęp do tego i pozostałych ponad 7000 artykułów
  • dostęp na 90 dni
  • oszczędzasz 28 zł
1. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9,1 million participants. The Lancet 2011; 377: 557- 567.
2. Grundy SM: Multifactorial causation of obesity: implication for prevention. Am J Clin Nutr 1998; 67: 563-572.
3. Hill JO, Peters JC: Environmental contributions to the obesity epidemic. Science 1998; 280: 1371-1374.
4. Kylin E: Studien ueber das Hypertonie-Hyperglykamie-Hyperurikamiesyndrom. Zentralblatt fuer Innere Medizin 1923; 44: 105-127.
5. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
6. Grundy SM, Cleeman JI, Daniels SR et al.: Diagnosis and management of the metabolic syndrome – An American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
7. Alberti KG, Eckel RH, Grundy SM et al.: Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
8. Wyrzykowski B, Zdrojewski T, Syganowska E et al.: Epidemiologia zespołu metabolicznego w Polsce. Wyniki programu WOBASZ. Kardiol Pol 2005; 63(4): S1-S4.
9. Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 2005; 365: 1415-1428.
10. Reaven G: Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
11. DeFronzo RA, Ferrannini E: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
12. Kaplan NM: The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149: 1514-1520.
13. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
14. Himpens J, Dobbeleir J, Peeters G: Long-term results of laparoscopic sleeve gastrectomy for obesity. Ann Surg 2010; 252: 319-324.
15. Hu G, Qiao Q, Tuomilehto J et al.: Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164: 1066-1076.
16. Isoma B, Almgren P, Tuomi T et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
17. Lakka HM, Laaksonen DE, Lakka TA et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716.
18. Vidal J, Ibarzabal A, Romero F et al.: Type 2 diabetes mellitus and the metabolic syndrome following sleeve gastrectomy in severely obese subjects. Obes Surg 2008; 18(9): 1077-1082.
19. Clinical Issues committee of the American Society for Metabolic and Bariatric Surgery: Sleeve gastrectomy as a bariatric procedure. Surg Obes Rel Dis 2007; 3: 573-576.
20. Kral JG, Naslund E: Surgical treatment of obesity. Nat Clin Pract Endocrinol Metab 2007; 3: 574-583.
21. WHO Fact sheet “Obesity and overweight” February 2018; http://www.who.int/mediacentre/factsheets/fs311/en/, downloaded 15-03-2018.
22. Hess DS, Hess DW: Biliopancreatic diversion with a duodenal switch. Obes Surg 1988; 8: 267-282.
23. Marceau P, Hould FS, Simard S et al.: Biliopancreatic diversion with duodenal switch. World J Surg 1988; 22(9): 947-954.
24. Xinze S, Shahzeer K: A review of laparoscopic sleeve gastrectomy for morbid obesity. Obes Surg 2010; 20: 1171-1177.
25. Buchwald H, Avidor Y, Brawnwald E et al.: A systematic review and meta-analysis. Jama 2004; 292: 1724-1737.
26. Rosiek A, Frackowiak-Maciejewska N, Leksowski K et al.: Effect of Television on Obesity and Excess of Weight and Consequences of Health. Int J Environ Res Public Health 2015; 12(8): 9408-9426.
27. Obesity Update June 2014, OECD; http://www.oecd.org/health/Obesity-Update-2014.pdf (data dostępu: 1.03.2016).
28. Hossain P, Kawar B, El Nahas M: Obesity and diabetes in the developing world – a growing challenge. N Engl J Med 2007; 356: 213-215.
29. Wylezol M, Pasnik K, Dabrowiecki S et al.: Polish recommendations for bariatric surgery. Videosurgery Mininv 2009; 4(1): 5-8.
30. Karamanakos SN, Vegenas K, Kalfarenteos F et al.: Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg 2008; 247(3): 401-407.
31. Shi X, Karmali S, Sharma AM et al.: A review of laparoscopic sleeve gastrectomy for morbid obesity. Obes Surg 2010; 20: 1171-1177.
32. Nocca D, Krawczykowsky D, Bomans B et al.: A prospective muliticenter study of 163 sleeve gastrectomies: results at 1 and 2 years. Obes Surg 2008; 18: 560-566.
33. Himpens J, Dobbeleir J, Peeters G: Long-term results of laparoscopic sleeve gastrectomy for obesity. Ann Surg 2010; 252: 319-324.
34. Hoyuela C: Five-year outcomes of laparoscopic sleeve gastrectomy as a primary procedure for morbid obesity: A prospective study. World J Gastrointest Surg 2017; 279(4): 109-117.
35. Chih-Kun H, Amit G, Hsin-Chih K et al.: Bariatric surgery in old age: a comparative study of laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy in an Asia centre of excellence. J Biomed Sci Res 2015; 29(2): 118-124.
36. Mio T, Miwa K, Yumi O et al.: Body Weight Reduction Program for Metabolic Syndrome – Evaluation of Effect after One-year-Intervention. Asian Pacific Journal of Disease Managment 2008; 2(3): 93-96.
37. Hutter MM, Schirmer BD, Jones DB et al.: First report from the American College of Surgeons Bariatric Surgery Center Network: laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass. Ann Surg 2011; 254(3): 410-420.
38. Carlin AM, Zeni TM, English WJ et al.: The comparative effectiveness of sleeve gastrectomy, gastric bypass, and adjustable gastric banding procedures for the treatment of morbid obesity. Ann Surg 2013; 257(5): 791-797.
39. Major P, Kowalczuk A, Budzyński A et al.: Effects of bariatric surgery on cardiovascular risk factors among morbidly obese patients. Pol Przegl Chir 2017; 89(1): 41-49.
40. Süleyman Ç, Hasan E, Recep A et al.: The effect of laparoscopic sleeve gastrectomy on morbid obesity and obesity-related comorbidities: A cohort study. Ulus Cerrahi Derg 2015; 31(4): 202-206.
41. D’Hondt M, Vanneste S, Pottel H et al.: Laparoscopic sleeve gastrectomy as a single-stage procedure for the treatment of morbid obesity and the resulting quality of life, resolution of comorbidities, food tolerance, and 6-year weight loss. Surgical Endoscopy 2011; 25(8): 2498-2504.
42. Favricatore AN, Wadden TA, Sarwer DB et al.: Health-related quality of life and symptoms of depression in extremely obese persons seeking bariatric surgery. Obes Surg 2005; 15: 304-309.
43. Padwal R, Klarenbach S, Wiebe N et al.: Bariatric surgery: a systematic review and network meta-analysis of randomized trials meta-analysis of randomized trials. Obes Rev 2011; 12(8): 602-621.
44. Gianfranco S, Boru C, Pecchia A et al.: Effectiveness of Laparoscopic Sleeve Gastrectomy (First Stage of Biliopancreatic Diversion with Duodenal Switch) on Co-Morbidities in Super-Obese High-Risk Patients. Obesity Surgery 2006; 16(9): 1138-1144.
otrzymano: 2018-03-02
zaakceptowano do druku: 2018-03-26

Adres do korespondencji:
*Hady Razak Hady
I Klinika Chirurgii Ogólnej
i Endokrynologicznej
Uniwersytecki Szpital Kliniczny
w Białymstoku
ul. M. Skłodowskiej-Curie 24A
15-276 Białystok
tel. +48 (85) 831-86-72

Postępy Nauk Medycznych 2/2018
Strona internetowa czasopisma Postępy Nauk Medycznych